Defining next generation DNA Damage Response Medicines
We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to specifically destroy certain devastating cancers that are difficult to treat.
Unparalleled Experience in DDR
We are Artios. We believe DDR-targeting therapies can play a significant role in the treatment of malignant disease, and we aim to take advantage of the full range of DDR therapeutic strategies to unlock new opportunities for patients.
Our team is recognized as innovators in DDR drug discovery, with experience that dates back to its inception. Our scientific founders, Niall Martin, PhD, and Graeme Smith, PhD, invented a blockbuster PARP inhibitor (now marketed as Lynparza® (olaparib) by AstraZeneca) and pioneered successful DDR programs while at KuDOS. Our industry-leading expertise in this space has yielded a robust pipeline and platform with immense potential which has led to collaborations with major pharma partners.
Our comprehensive approach exploits the full range of DDR-based therapeutic opportunities.
Our capabilities allow us to move beyond a single approach, such as synthetic lethality, to develop drugs with a broad range of applications. Our approach includes developing inhibitors with monotherapy potential, overcoming acquired or de novo resistance to existing DDR-targeted therapies, including PARP inhibitors, supercharging existing DNA-targeting treatments through combinations, and expanding the reach of the immune response.
Our orally dosed ataxia telangiectasia and Rad3-related protein (ATR) inhibitor, ART0380, has the potential to induce DNA damage in sensitive cancer tissue while preserving DNA integrity in healthy tissue. ART0380 is being developed as an oral anticancer agent as both a monotherapy and in combination with established as well as novel agents that cause DNA damage or suppress a cancer cell’s ability to repair DNA damage.Learn more
Our inhibitor offers the unprecedented potential to harness the power of the DDR inhibition to specifically target tumor cells while sparing normal tissue from toxicity. It may allow for effective and widespread use across multiple tumor types including PARP inhibitor resistant cancers, as a combination treatment with other DDR inhibitors, or in combination with DNA damaging agents.Learn more
In March 2021, Artios entered into a research collaboration and license agreement with Novartis; a global healthcare company based in Switzerland (https://www.novartis.co.uk/ ) to identify DNA Damage Response (DDR) targets and the agents capable of modulating these targets, for use with Novartis’s proprietary radioligand therapies or as a monotherapy.Learn more
In December 2020, Artios entered into a research collaboration and license agreement with Merck KGaA , Pharmaceutical company in Darmstadt, Germany, a leading team of specialists in Healthcare and Life Sciences (https://www.merckgroup.com/en/company.html) for the identification of novel DDR nuclease inhibitors in the oncology field.Learn more
Alternative Lengthening of Telomeres (ALT)
The development of our DDR platform has given us the ability to identify novel DDR targets in relevant disease setting where there is unmet medical need.
Immuno- oncology Combinations
Medicines that enable the immune system to target and kill cancer cells (immunotherapy) are therapeutics that have proven to be a highly effective means of treating a select group of cancers.Learn more
In the news
Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer
Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023
Advancement Through Partnership
We believe DDR-based therapies have more opportunity than we can explore alone, and we look to leverage our expertise and maximize the long-term value of our discoveries with strategic partnerships.